Rate My Professor David Al-Adra

His research laboratory investigates key areas in transplantation immunology and oncology. In transplant immunology, he explores the therapeutic potential of normothermic ex-vivo perfusion systems to promote organ transplant acceptance by modifying immunological effects on grafts, including altering graft-resident immune cells and cellular surface molecules to foster a regulatory environment and reduce the need for induction and maintenance immunosuppression. In transplant oncology, his work identifies novel biomarkers for prognosis and treatment targets in patients undergoing liver transplantation for hepatocellular carcinoma, emphasizing early detection via circulating tumor cells and tumor nucleic acids, mechanisms of cancer progression, and targeted therapies. Dr. Al-Adra has secured major funding, including a two-year $100,000 Collaborative Scientist Grant from the American Society of Transplant Surgeons, a one-year $50,000 Pilot Research Award from the American Association for the Study of Liver Diseases Foundation, a one-year $65,000 grant from the University of Wisconsin's 2023 Fall Research Competition, and recognition as an Avant-Garde Health General Surgery Research All-Stars in 2024. Notable publications include 'Dual Kidney Transplantation Offers Prolonged Graft Survival' (Clinical Transplantation, 2026), 'Rethinking the use of immunotherapy post-liver transplantation: Standardized protocols with low risk of rejection' (Liver Transplantation, 2025), 'Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ Transplantation' (Urology, 2026), 'Importing pancreata for transplantation: a single-center experience across evolving allocation eras' (Frontiers in Transplantation, 2025), and 'De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care' (Clinical Transplantation, 2025).